These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33345392)

  • 1. Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1.
    Chu Y; Bucci JC; Peterson CB
    Protein Sci; 2021 Mar; 30(3):597-612. PubMed ID: 33345392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.
    Bucci JC; Trelle MB; McClintock CS; Qureshi T; Jørgensen TJ; Peterson CB
    Biochemistry; 2016 Aug; 55(31):4386-98. PubMed ID: 27416303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolving distinct molecular origins for copper effects on PAI-1.
    Bucci JC; McClintock CS; Chu Y; Ware GL; McConnell KD; Emerson JP; Peterson CB
    J Biol Inorg Chem; 2017 Oct; 22(7):1123-1135. PubMed ID: 28913669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
    Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
    Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
    Wang Z; Mottonen J; Goldsmith EJ
    Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
    Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
    J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.
    Thompson LC; Goswami S; Ginsberg DS; Day DE; Verhamme IM; Peterson CB
    Protein Sci; 2011 Feb; 20(2):353-65. PubMed ID: 21280127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.
    Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M
    J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
    Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
    Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
    Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
    Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies.
    Lee HJ; Im H
    Protein Expr Purif; 2003 Sep; 31(1):99-107. PubMed ID: 12963346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues.
    Gettins PG; Dolmer K
    J Biol Chem; 2016 Jan; 291(2):800-12. PubMed ID: 26555266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.